Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats

Brazilian Oral Research

Volumn 21, Issue 4, 2007, Pages 293-297

  Nassar, Carlos Augusto ^a,c   Nassar, Patricia Oehlmeyer ^a   Andia, Denise Carleto ^b   Guimarães, Morgana Rodrigues ^b   Pepato, Maria Teresa ^b   Spolidorio, Luis Carlos ^b  

^a Unioeste   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c NONE   (Brazil)

Author keywords

Diabetes mellitus; Glycemic index; Rats; Tacrolimus adverse effects

Indexed keywords

EID: 37349071053     PISSN: 18068324     EISSN: 18073107     Source Type: Journal    
DOI: 10.1590/s1806-83242007000400002     Document Type: Article

References (11)

1. Caldeira TC, Nassar CA, Massucato SEM, Orrico SRP, Nassar PO. Diabetes mellitus and periodontal disease: A bidirectional relation. Diabetes Clinica. 2005;9(3):212-7.
2. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68(3):396-402.
3. Ishida H, Mitamura T, Takahashi Y, Hisatomi A, Fukuhara Y, Murato K et al. Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. Toxicology. 1997;123(3):167-75.
4. Jiang H, Fujitsu T, Sakuma S, Ogawa T, Tamura K, Fujii Y et al. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. Transplant Proc. 1995;27(1):367-9.
5. Jiang H, Takahara S, Takano Y, Li D, Kyo M, Valdivia LA et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rat in comparison with cyclosporine. Transplant Proc. 1991;23(1Pt1):540-1.
6. Kasiske B, Snyder JJ, Gilbertson D, Matas A. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178-85.
7. Maes BD, Kuypers D, Messiaen T, Evenepoel P, Mathieu C, Coosemans W et al. Posttransplantation diabetes mellitus in FK-506 treated renal transplant recipients: Analysis of incidence and risk factors. Transplantation. 2001;72(10):1655-61.
8. Mitruka BM, Rawnsley HM. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans. 2nd ed, Section VI, p. 160. New York: Masson; 1977.
9. Van Hooff JP, Van Duijnhoven EM, Christiaans MHL. Tacrolimus and glucose metabolism. Transplant Proc. 1999;31(7A):49S-50S.
10. Voggenreiter G, Siozos P, Hunkemoller E, Heute S, Schwarz M, Obertacke U. Immunosuppression with FK506 has no influence on fracture healing in the rat. Bone. 2005;37(2):227-33.
11. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;19(4):CD003961. DOI: 10.1002/14651858.CD003961.